Trials / Completed
CompletedNCT00002163
A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.
Detailed description
Patients must be on stable antiretroviral treatment for at least 6 weeks prior to study entry and will then be stratified depending on whether their regimen contains zidovudine (ZDV). Each stratum will be randomized separately to receive 1592U89 or placebo for 12 weeks. For the subsequent 40 weeks, open-label 1592U89 will be offered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abacavir sulfate |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
9 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00002163. Inclusion in this directory is not an endorsement.